108 related articles for article (PubMed ID: 19255304)
1. Bevacizumab and postoperative complications after hepatic surgery for colorectal metastases.
Petrelli NJ
J Clin Oncol; 2009 Apr; 27(11):1917; author reply 1918. PubMed ID: 19255304
[No Abstract] [Full Text] [Related]
2. How many patients and how many complications does it take to decide if a drug is safe to use before surgery?
Kemeny MM
J Clin Oncol; 2009 Apr; 27(11):1917-8; author reply 1918. PubMed ID: 19255303
[No Abstract] [Full Text] [Related]
3. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study.
D'Angelica M; Kornprat P; Gonen M; Chung KY; Jarnagin WR; DeMatteo RP; Fong Y; Kemeny N; Blumgart LH; Saltz LB
Ann Surg Oncol; 2007 Feb; 14(2):759-65. PubMed ID: 17103075
[TBL] [Abstract][Full Text] [Related]
4. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases.
Kesmodel SB; Ellis LM; Lin E; Chang GJ; Abdalla EK; Kopetz S; Vauthey JN; Rodriguez-Bigas MA; Curley SA; Feig BW
J Clin Oncol; 2008 Nov; 26(32):5254-60. PubMed ID: 18854565
[TBL] [Abstract][Full Text] [Related]
5. In search of the black sheep: is it bevacizumab or extended chemotherapy?
Vauthey JN; Zorzi D
Ann Surg Oncol; 2009 Jun; 16(6):1463-4. PubMed ID: 19357926
[No Abstract] [Full Text] [Related]
6. Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study.
Tamandl D; Gruenberger B; Klinger M; Herberger B; Kaczirek K; Fleischmann E; Gruenberger T
Ann Surg; 2010 Jul; 252(1):124-30. PubMed ID: 20562613
[TBL] [Abstract][Full Text] [Related]
7. Perioperative risks of bevacizumab and other biologic agents for hepatectomy: theoretical or evidence based?
Bilchik AJ; Hecht JR
J Clin Oncol; 2008 Apr; 26(11):1786-8. PubMed ID: 18398144
[No Abstract] [Full Text] [Related]
8. Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver.
Cleary JM; Tanabe KT; Lauwers GY; Zhu AX
Oncologist; 2009 Nov; 14(11):1095-105. PubMed ID: 19880627
[TBL] [Abstract][Full Text] [Related]
9. Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab.
Aussilhou B; Dokmak S; Faivre S; Paradis V; Vilgrain V; Belghiti J
Ann Surg Oncol; 2009 Jun; 16(6):1553-9. PubMed ID: 19363584
[TBL] [Abstract][Full Text] [Related]
10. Hepatic veno-occlusive disease after neoadjuvant treatment of colorectal liver metastases with oxaliplatin: a lesson of the month.
Schouten van der Velden AP; Punt CJ; Van Krieken JH; Derleyn VA; Ruers TJ
Eur J Surg Oncol; 2008 Mar; 34(3):353-5. PubMed ID: 17207961
[TBL] [Abstract][Full Text] [Related]
11. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab.
Yoo PS; Lopez-Soler RI; Longo WE; Cha CH
Clin Colorectal Cancer; 2006 Sep; 6(3):202-7. PubMed ID: 17026789
[TBL] [Abstract][Full Text] [Related]
12. Biologic modulation of chemotherapy in patients with hepatic colorectal metastases: the role of anti-VEGF and anti-EGFR antibodies.
Geva R; Prenen H; Topal B; Aerts R; Vannoote J; Van Cutsem E
J Surg Oncol; 2010 Dec; 102(8):937-45. PubMed ID: 21165996
[TBL] [Abstract][Full Text] [Related]
13. Portal venous gas following chemotherapy for colorectal cancer liver metastasis.
Zalinski S; Scatton O; Jacqmin S; Tacher V; Brézault C; Soubrane O
Eur J Surg Oncol; 2009 May; 35(5):557-60. PubMed ID: 18950980
[TBL] [Abstract][Full Text] [Related]
14. Volumetric analysis of remnant liver regeneration after major hepatectomy in bevacizumab-treated patients: a case-matched study in 82 patients.
Millet G; Truant S; Leteurtre E; Hebbar M; Zerbib P; Huet G; Boleslawski E; Pruvot FR
Ann Surg; 2012 Nov; 256(5):755-61; discussion 761-2. PubMed ID: 23095619
[TBL] [Abstract][Full Text] [Related]
15. Locoregional strategies for colorectal hepatic metastases.
Meyers MO; Sasson AR; Sigurdson ER
Clin Colorectal Cancer; 2003 May; 3(1):34-44. PubMed ID: 12777190
[TBL] [Abstract][Full Text] [Related]
16. Evolution of neoadjuvant therapy for extended hepatic metastases--have we reached our (non-resectable) limit?
Adam R; Hoti E; Bredt LC
J Surg Oncol; 2010 Dec; 102(8):922-31. PubMed ID: 21165994
[TBL] [Abstract][Full Text] [Related]
17. [Roles of hepatectomy for colorectal liver metastases with necrotic foci caused by prior anti-cancer therapies].
Ko S; Mukogawa T; Ishikawa H; Inoue T; Nishiwada T; Nakamoto T; Kunishige T; Watanabe A
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2569-72. PubMed ID: 21224642
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant therapy of colorectal liver metastases: lessons learned from clinical trials.
Brouquet A; Nordlinger B
J Surg Oncol; 2010 Dec; 102(8):932-6. PubMed ID: 21165995
[TBL] [Abstract][Full Text] [Related]
19. Curing patients with liver metastases from colorectal cancer.
Drug Ther Bull; 2011 Apr; 49(4):42-5; quiz i-ii. PubMed ID: 21467575
[TBL] [Abstract][Full Text] [Related]
20. Optimizing resection for "responding" hepatic metastases after neoadjuvant chemotherapy.
Thomay AA; Charpentier KP
J Surg Oncol; 2010 Dec; 102(8):1002-8. PubMed ID: 20734423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
